Alnylam Pharmaceuticals, Inc., 10% Owner at Regulus Therapeutics Inc. (RGLS), sold 8,900 shares at $7.70 ($70K) on 2014-09-10, disclosed to the SEC on 2014-09-12.
Scheduled sale ($70k) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.70 | 2,000 | $15K | 22.0% |
| 2 | $7.83 | 3,400 | $27K | 38.1% |
| 3 | $7.96 | 3,500 | $28K | 39.9% |
| Total | $7.85 avg | 8,900 | $70K | 100% |
| Filing → |
| RGLS | SELL | 2014-10-24 | $1.6M | — | Filing → |
| RGLS | SELL | 2014-10-17 | $81K | — | Filing → |
| RGLS | SELL | 2014-10-10 | $66K | — | Filing → |